|1.||Fischer-Colbrie, Reiner: 10 articles (01/2015 - 06/2003)|
|2.||Kirchmair, Rudolf: 7 articles (01/2015 - 09/2007)|
|3.||Stridsberg, Mats: 6 articles (02/2015 - 06/2008)|
|4.||Schgoer, Wilfried: 6 articles (01/2015 - 09/2007)|
|5.||Theurl, Markus: 6 articles (01/2015 - 09/2007)|
|6.||Fischer-Colbrie, R: 5 articles (04/2005 - 01/2000)|
|7.||Albrecht-Schgoer, Karin: 4 articles (01/2015 - 11/2012)|
|8.||Lener, Daniela: 3 articles (01/2015 - 01/2013)|
|9.||Beer, Arno G E: 3 articles (11/2012 - 09/2007)|
|10.||Troger, Josef: 3 articles (09/2008 - 07/2003)|
01/01/2013 - "Secretoneurin gene therapy improves blood flow in an ischemia model in type 1 diabetic mice by enhancing therapeutic neovascularization."
11/06/2009 - "In the mouse hindlimb ischemia model secretoneurin gene therapy by intramuscular plasmid injection significantly increased secretoneurin content of injected muscles, improved functional parameters, reduced tissue necrosis, and restored blood perfusion. "
01/01/2013 - "Based on our previous work where we demonstrated that Secretoneurin (SN) is up-regulated under hypoxic conditions and enhances angiogenesis, we analyzed the therapeutic potential of SN gene therapy using a model of severe hind limb ischemia in streptozotocin-induced diabetic mice (STZ-DM). "
11/06/2009 - "In summary, our data indicate that gene therapy with secretoneurin induces therapeutic angiogenesis, arteriogenesis, and vasculogenesis in the hindlimb ischemia model by a nitric oxide-dependent mechanism."
09/01/2007 - "In vivo, muscle cells of mouse ischemic hind limbs showed increased secretoneurin expression, and inhibition of secretoneurin by a neutralizing antibody impaired the angiogenic response in this ischemia model. "
|4.||Carcinoid Tumor (Carcinoid)
06/05/2008 - "Even though secretoneurin was not as frequently increased as CgA and CgB in patients with carcinoid tumours or pheochromocytoma it may be a useful marker for endocrine pancreatic tumours."
11/01/1998 - "Our investigations revealed that secretoneurin is detected more frequently than chromogranin A in carcinoids of the appendix. "
11/01/1998 - "Secretoneurin in carcinoids of the appendix-immunohistochemical comparison with chromogranins A,B and secretogranin II."
04/01/1995 - "Secretoneurin in bronchopulmonary carcinoids--immunohistochemical comparison with chromogranins A and B and secretogranin II."
11/30/2010 - "Antisera to the secretogranin II-derived peptide, secretoneurin detects carcinoid tumors of the appendix with greater frequency than antisera to CgA and are of value in identifying therapy-resistant carcinoma of the prostate (clinical stage D3). "
10/01/2000 - "Secretoneurin (SN) is a neuropeptide that is chemotactic for mononuclear cells and it has been suggested to be involved in the mediation of pain; there is also evidence that SN is involved in the inflammation process. "
04/01/2005 - "Nasal capsaicin challenge produced local pain (P <0.05) and increased the levels of fucose (P <0.05), but failed to affect the levels of secretoneurin. "
09/01/1998 - "Because former investigations have reported abnormal changes in the expression of serotonin (5-hydroxytryptamine [5-HT]) and substance P (SP) in serum and cerebrospinal fluid, this study sought to determine whether 5-HT and pain-modulating neuropeptides (SP, galanin [GA], pituitary adenylyl cyclase-activating polypeptide, and secretoneurin) were expressed abnormally in the muscle tissue of patients with fibromyalgia (FM). "
|6.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|7.||Matrix Metalloproteinase 9 (Gelatinase B)
|8.||Bone Morphogenetic Proteins (Bone Morphogenetic Protein)
|10.||Serotonin (5 Hydroxytryptamine)
|1.||Cardiopulmonary Resuscitation (CPR)